Mounjaro KwikPen (Tirzepatide)

Mounjaro is a prescription medication containing Tirzepatide, developed by Eli Lilly and Company. It was originally FDA-approved in May 2022 for the treatment of type 2 diabetes and later approved for weight management under different brand names. The brand is synonymous with metabolic health innovation and is part of a new class of dual-agonist medications.

Manufacturing for Mounjaro and its delivery system (the KwikPen) is a global operation. Eli Lilly maintains significant production facilities in the United States (specifically Indiana and North Carolina) and Ireland. Due to high global demand, the company has heavily invested in expanding its manufacturing footprint across multiple international sites to ensure supply chain stability.

Eli Lilly and Company is one of the world's largest pharmaceutical entities, headquartered in Indianapolis, Indiana. Founded in 1876, it remains an independent, publicly traded corporation. The brand Mounjaro is owned entirely by Eli Lilly, which manages its research, development, and distribution globally through various regional subsidiaries.